🇺🇸 FDA
Patent

US 7521049

Use of VEGF inhibitors for treatment of eye disorders

granted A61KA61K38/00A61K38/179

Quick answer

US patent 7521049 (Use of VEGF inhibitors for treatment of eye disorders) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61K38/179